Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature

医学 伦瓦提尼 吉西他滨 化疗 放射科 肿瘤科 内科学 肝细胞癌 索拉非尼
作者
Qinqin Liu,Xianhuan Yu,Qibin Tang,Dong Chen,Rui Zhang,Chao Liu,Xiang-de Shi
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
被引量:2
标识
DOI:10.1097/cad.0000000000001519
摘要

Perihilar cholangiocarcinoma is a refractory malignancy with an unfavorable prognosis and a high probability of recurrence. Systemic chemotherapy is critical for palliative treatment, but effective therapeutic strategies for perihilar cholangiocarcinoma after first-line chemotherapy failure are scarce. Here, we introduced a sustained benefit following sintilimab combined with lenvatinib plus S-1 in a patient with recurrent perihilar cholangiocarcinoma. A 52-year-old female patient was admitted to our hospital due to yellow skin and sclera, and further radiological examination revealed perihilar cholangiocarcinoma. The patient underwent surgery and histopathological results confirmed moderately differentiated adenocarcinoma with metastatic lymph nodes. Postoperative adjuvant chemotherapy with gemcitabine and S-1 was given. One year after surgery, the patient experienced hepatic recurrence. Then, she received radiofrequency ablation combined with gemcitabine and cisplatin. Unfortunately, radiological assessment revealed progressive disease with multiple liver metastases after treatment. Subsequently, she received sintilimab combined with lenvatinib plus S-1 and the lesions were completely regressed following 14 cycles of combination therapy. The patient recovered well without disease recurrence at the last follow-up. Sintilimab combined with lenvatinib plus S-1 may be an alternative therapeutic option for chemotherapy-refractory perihilar cholangiocarcinoma, and further evaluation in a larger number of patients is needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
我是老大应助贾方硕采纳,获得10
2秒前
无情的宛菡完成签到 ,获得积分10
2秒前
淡淡一德发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
量子星尘发布了新的文献求助10
4秒前
易今发布了新的文献求助10
4秒前
tom发布了新的文献求助10
4秒前
5秒前
nuaahq发布了新的文献求助10
5秒前
懵懂的十三关注了科研通微信公众号
5秒前
小巧凡霜发布了新的文献求助10
6秒前
6秒前
星辰大海应助白泽采纳,获得10
7秒前
希望天下0贩的0应助th采纳,获得10
7秒前
尔东发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
8秒前
桐桐应助11采纳,获得10
8秒前
9秒前
Apricot发布了新的文献求助10
9秒前
一洼清泉发布了新的文献求助30
10秒前
猴哥完成签到,获得积分10
10秒前
kkkk发布了新的文献求助10
11秒前
开放善斓发布了新的文献求助30
11秒前
11秒前
11秒前
12秒前
贾方硕发布了新的文献求助10
12秒前
在不在发布了新的文献求助10
13秒前
852应助现代雪柳采纳,获得10
13秒前
周shang发布了新的文献求助10
13秒前
14秒前
华仔应助没有名字行不行采纳,获得10
15秒前
彭于晏应助义气的雨旋采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Target genes for RNAi in pest control: A comprehensive overview 500
A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels 500
Textbook of Neonatal Resuscitation ® 500
The Affinity Designer Manual - Version 2: A Step-by-Step Beginner's Guide 500
Affinity Designer Essentials: A Complete Guide to Vector Art: Your Ultimate Handbook for High-Quality Vector Graphics 500
Optimisation de cristallisation en solution de deux composés organiques en vue de leur purification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5086463
求助须知:如何正确求助?哪些是违规求助? 4302233
关于积分的说明 13407203
捐赠科研通 4127429
什么是DOI,文献DOI怎么找? 2260309
邀请新用户注册赠送积分活动 1264536
关于科研通互助平台的介绍 1198741